The cholesterol lowering atherosclerosis study evaluated the effect of lipid lowering on structural angiographic endpoints in 162 patients and related these results with functional clinical endpoints. IVUS analysis at 12 months showed a decrease in plaque area, and a rise in minimal lumen diameter from research beginning in the LDL A group and a reverse effect, in the medicine only group. Similarly excellent results were recently noticed in Research to Evaluate the Effect E3 ubiquitin ligase inhibitor of Rosuvastatin on Intravascular Ultrasound Derived Coronary Atheroma Burden. Intensive lipid lowering with 40 mg Rosuvastatin in the 349 people who’d 24-month follow up caused a reduction in LDL cholesterol by 53. 4% and a rise in HDL cholesterol by 14. 6% from baseline. Typical reduced amount of total atheroma volume from baseline was 6. 800-acre after two years of intensive treatment by rosuvastatin. The effect of lipid lowering treatment on plaque composition was highlighted in another study that compared the effect of 20mg atorvastatin versus typical care among patients with coronary artery illness. At 12-month follow up plaque volume and plaque echogenicity was assessed by IVUS. Mean complete plaque volume showed a more substantial increase in the usual care group compared with the atorvastatin group. The hyperechogenicity catalog, a marker of plaque composition, increased to a bigger extent for the atorvastatin group than for the normal treatment group, with an important treatment effect Cholangiocarcinoma for the percent change. The Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial assessing the function of 80 mg of simvastatin with or without 10 mg of Ezetimibe in 720 patients with familial hypercholesterolemia unmasked that combination therapy did not create a significant reduction in CIMT after 24 months of therapy. Still another newer 3-year test, Stop Atherosclerosis in Indigenous Diabetics Study, compared the effect of standard therapy with c-Met Inhibitor lifestyle modification Simvastatin to attain old-fashioned goals for LDL C, non-hdl C, and SBP, to intense therapy with lifestyle modification Simvastatin Ezetimibe to achieve goals of 70 mg/dL, 100 mg/dL, and 115mmHg, respectively. From the end-of the 3-year period, the CIMT progressed within the typical therapy group and regressed in the intense therapy group, P.. 0001. There is no additional benefit of adding Ezetimibe to Simvastatin on CIMT regression in patients who reached their target LDL C. Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin study, the greatest placebo controlled statin trial assessing the effects of Rosuvastatin on CIMT in low-risk individuals, showed a considerable regression in CIMT compared to placebo which did not reflect on an optimistic clinical cardiovascular outcome. Yet another interesting unpublished 1 year clinical trial, the CASHMERE, assessing the consequence of 80mg of atorvastatin compared to placebo in 399 post menopausal women, found no statistical difference in CIMT effects.